KBio

KBio is now on LinkedIn! KBio is a #biotech company leveraging our #plantbased platform to enhance R&D productivity with the aim of delivering biologics at a fraction of the time and cost of current approaches. KBio has built a team of experts in #virology, plant expression and therapeutics to support and advance its growing clinical-stage pipeline of mAbs and vaccines. We’re on a mission to create the next generation of #biologics in areas of high unmet need. Follow us to learn more about our science and stay up to date on all KBio’s news and breakthroughs.

We're pleased to announce a three-year supply agreement with Merck to use our #PlantBased platform to develop recombinant aprotinin. Aprotinin is a potent serine protease inhibitor used in a wide variety of applications. We look forward to supporting Merck's work with our cost-effective approach. Learn more here: https://bit.ly/4eS20Vn

At KBio, we nurture our team and are guided by our ethos: 🌱 WE ARE… ROOTED IN COLLABORATION: Strong partnerships are our foundation. Through teamwork and open communication, we achieve greater success together. 🌿 WE VALUE… NURTURED GROWTH: We foster continuous learning and skill development, helping our team members thrive and contribute to our collective achievements. 🌟 WE ENCOURAGE… ORGANIC INNOVATION: We embrace fresh ideas and adaptability, creating an environment where innovation flourishes, keeping us at the forefront of health and medicine.

We’re pleased to announce a three-year supply agreement with Sigma/Merck to use our #PlantBased platform to develop recombinant aprotinin. Aprotinin is a potent serine protease inhibitor used in a wide variety of applications. We look forward to supporting Sigma/Merck’s work with our cost-effective approach.

While monoclonal antibodies (mAbs) have been pivotal in the treatment of different types of disease, traditional mAb manufacturing faces several challenges including: - scaling issues - lengthy production timelines - environmental concerns (high water usage and waste) That's why we've developed a #PlantBased protein production process with the potential to overcome these challenges. Learn more about our work at KBio here: https://bit.ly/4c5hbZT

🌿💡 Our Rapid Protein Production Platform (RP3) revolutionizes biologic manufacturing with a #PlantBased approach. Utilizing proprietary seeds and advanced vertical farming, RP3 offers a scalable, sustainable, and cost-effective method to produce high-quality biologics. Learn more about how RP3 is transforming the future of biologic production: https://bit.ly/3KVaI7Z

We are thrilled to announce that KBio was featured in the summer issue of Drug Discovery World! Our Head of Research, Dr. Carmine Carpenito, emphasizes the importance of developing versatile therapeutic treatments to improve survival chances, particularly for tumors prone to resistance. Read the article here: https://bit.ly/4cHqZcf

Today, we announced that we have received IND clearance and dosed the first patient in the Phase 1 study of a treatment for #AcuteFlaccidMyelitis (#AFM). We look forward to continuing enrollment and providing hope to patients with a potential new treatment. Read more in our press release: https://bit.ly/4bmjiY3.

In August 2023, we announced a strategic partnership with ZERO to build the world’s first transportable globally distributed plant-based molecular farming network to include therapeutic, pandemic preparedness and bioactive ingredient production. Learn more about our collaboration here: https://lnkd.in/gPCPz8CP

The speed and efficiency demonstrated by our proprietary platform has significant potential, supporting our goal to develop novel antibody therapies. Learn more about our ongoing work here: https://lnkd.in/eX8wbm8k